QQ客服 官方微博 反馈留言

	Efficacy and safety of afatinib in a Chinese population with advanced lung adenocarcinoma with sensitive EGFR mutations
	Wang, Shouzheng; Xing, Puyuan; Yang, Ke; Hao, Xuezhi; Ma, Di; Mu, Yuxin; Li, Junling
	2019
卷号	10期号:6页码:1461-1468
关键词	Afatinib lung adenocarcinoma non-small-cell lung ErbB receptors molecular targeted therapy
ISSN号	1759-7706
DOI	10.1111/1759-7714.13095
URL标识	查看原文
收录类别	SCIE ; PUBMED
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6341662
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Wang, Shouzheng,Xing, Puyuan,Yang, Ke,et al. Efficacy and safety of afatinib in a Chinese population with advanced lung adenocarcinoma with sensitive EGFR mutations[J],2019,10(6):1461-1468.
APA	Wang, Shouzheng.,Xing, Puyuan.,Yang, Ke.,Hao, Xuezhi.,Ma, Di.,...&Li, Junling.(2019).Efficacy and safety of afatinib in a Chinese population with advanced lung adenocarcinoma with sensitive EGFR mutations.,10(6),1461-1468.
MLA	Wang, Shouzheng,et al."Efficacy and safety of afatinib in a Chinese population with advanced lung adenocarcinoma with sensitive EGFR mutations".10.6(2019):1461-1468.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。